Please assess the completion status of the following clinical trial:

Trial Title: Psilocybin Cancer Anxiety Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-76~* Current or historical diagnosis of cancer~* Projected life expectancy of at least one year~* DSM-IV diagnoses: Acute Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder due to cancer, Adjustment Disorder with anxious features~* Any stage of cancer diagnosis~Exclusion Criteria:~* Epilepsy~* Renal disease~* Diabetes~* Abnormal liver function~* Severe cardiovascular disease~* Malignant Hypertension~* Baseline blood pressure must be less than or equal to 140/90~* Personal history or immediate family members with schizophrenia, bipolar affective disorder, delusional disorder, schizoaffective disorder or other psychotic spectrum illness~* Current substance use disorder~* Medication contraindications: anti-seizures medications, insulin, oral hypoglycemics, clonidine, aldomet, cardiovascular medications, anti-psychotics (first and second generation), anti-depressants and mood stabilizers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): Drug intervention
- Niacin (Type: ACTIVE_COMPARATOR): Active control

Based on this trial design, predict the completion outcome and termination type (if applicable).